The equity crowdfunding campaign for medical device company Ezalise is entering its final days on the StartEngine platform, with the investment opportunity scheduled to close on April 6. The company has developed the Button Huggie® device, which is registered with the U.S. Food and Drug Administration and designed to address a critical healthcare challenge: securing feeding tubes for patients who require them. According to company data, over 1 million families annually are impacted by issues related to feeding tube security.
Ezalife was founded by a pediatric surgeon who observed the limitations of existing feeding tube securement methods in clinical practice. The company's solution emphasizes simplicity, safety, and reliability in its design. Clinical testing has demonstrated that the Button Huggie® device achieves a 77% reduction in feeding tube dislodgement compared to traditional methods. This improvement addresses both patient safety concerns and the clinical burden associated with tube replacement procedures.
The company has reported early commercial traction, including $8,000 in pre-orders and $11,000 in sales during its first month of product availability. Ezalife has also received backing from established healthcare institutions, including Children’s Hospital Colorado and CU Innovations. The company holds granted patents with global protection and has identified potential future products in its development pipeline.
With momentum building across clinical and consumer channels, Ezalife leadership stated the company is now focused on scaling distribution and expanding access to both patients and healthcare providers. "This is a pivotal moment for the company," company representatives noted. "We’ve built the foundation, now we’re focused on growth." Investors interested in participating in the equity crowdfunding round have a limited window before the campaign closes on April 6. More information about the investment opportunity is available through the campaign page at https://www.startengine.com/offering/ezalife.
